Key Stats for Boston Scientific Stock
- Past-Week Performance: +3%
- 52-Week Range: $72.7 to $109.5
- Current Price: $76.2
What Happened?
Boston Scientific‘s 17.6% single-day drop to $75.50 on February 4 obscures a business that just delivered 15.8% organic revenue growth and 22% EPS growth for full-year 2025, trading near its 52-week low of $72.69.
The selloff accelerated after Q4 electrophysiology growth of 35% missed inflated Street expectations of 25% market growth, triggering securities fraud investigations from both Pomerantz LLP on February 24 and Levi & Korsinsky on March 2.
Beneath the EP noise, Boston Scientific’s free cash flow surged 38% to $3.659B in 2025, and management guided 2026 adjusted EPS of $3.43 to $3.49, representing 12% to 14% growth on top of three consecutive years of 20%-plus EPS gains.
The CHAMPION trial late-breaker presentation at ACC on March 28 adds immediate urgency, as a positive result could expand WATCHMAN’s addressable patient pool from roughly 5M to 20M globally, directly supporting the long-range plan.
Chairman and CEO Michael Mahoney stated on the Q4 earnings call that “if you add all the other competitors together, our share will be equal to them,” directly ahead of the March 28 CHAMPION readout that could redefine WATCHMAN’s market.
With a $6B term loan facility signed February 26 to fund the Penumbra acquisition, Boston Scientific is entering mechanical thrombectomy and neurovascular markets where it currently has zero presence, widening its competitive moat well into 2030.
Wall Street’s Take on BSX Stock
The securities fraud investigations from Pomerantz and Levi & Korsinsky landed on a stock already trading 30% below its 52-week high, yet the underlying 2026 guidance of 12% to 14% EPS growth remains fully intact.
The fundamental trajectory stays compelling, with revenue accelerating from $16.8B in 2024 to $20.1B in 2025 and consensus projecting $22.3B in 2026, while normalized EPS grows from $3.06 to an estimated $3.46.
Despite the selloff, Wall Street holds 25 buys and 9 outperforms against just 1 hold as of March 2, with a mean price target of $104.75 implying 37.4% upside from $76.22, reflecting analysts buying conviction into the weakness.
The target range stretches from $83 on the low end to $124 on the high, where the March 28 CHAMPION trial readout at ACC determines which scenario plays out for WATCHMAN’s addressable market of 5M versus 20M patients.
What Does the Valuation Model Say?
The TIKR mid-case model sets a target of $128.37 against $76.22 today, projecting a 68.4% total return over 4.8 years at an 11.4% annualized IRR.
The market is punishing a perceived EP growth miss while ignoring that free cash flow surged 38% to $3.659B in 2025 with $4.2B guided for 2026.
Boston Scientific’s EBIT margins expanded to 28% in 2025 and are forecast to reach 28.5% in 2026, a business compressing is not what these numbers show.
Management signed a $6B term loan on February 26 to fund Penumbra, signaling the kind of balance sheet confidence that contradicts a thesis built on deceleration.
However, if the Penumbra acquisition closes and integrates poorly, gross debt leverage of 1.9x could strain the capital structure and delay the margin expansion roadmap.
The March 28 CHAMPION trial readout at ACC will immediately signal whether WATCHMAN’s market expands from 5M to 20M patients and validates the entire growth rerating.
BSX is deeply undervalued at $76.22 given a $128.37 mid-case target and a 68.4% potential total return; CHAMPION on March 28 is the inflection to watch.
Should You Invest in Boston Scientific Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up BSX stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Boston Scientific Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze BSX stock on TIKR for Free →
